Argenx SE announced positive efficacy data from its Phase 3 ADAPT OCULUS trial evaluating VYVGART as a treatment for ocular myasthenia gravis (oMG), a rare neuromuscular disorder affecting the eye muscles. The study met its primary endpoint, demonstrating statistically significant improvements in patient-reported outcomes. The favorable results position the company to pursue a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration to expand VYVGART's approved indication to include oMG treatment.
The clinical milestone arrives alongside strong financial performance in the fourth quarter. Argenx reported earnings per share of $8.02, surpassing consensus analyst expectations of $6.02, while quarterly revenues reached $1.32 billion against a consensus forecast of $1.29 billion. The robust financial results reflect growing commercial traction for VYVGART, which is currently approved for generalized myasthenia gravis.
The trial results represent a potential expansion opportunity for the company's flagship immunology asset in a patient population with limited treatment options. Subject to regulatory review and approval, the oMG indication could broaden VYVGART's addressable market and strengthen Argenx's competitive position in the myasthenia gravis therapeutic space.